Tiapride as Treatment for Certain Patients with Idiopathic Torsion Dystonia

Arlazoroff, A; Klein, Colin; Meiner, Zeev; Milo, Ron; Theitler, Jacques; Carpel, Clive L.

doi:10.1159/000116693

Cited by 4 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Five patients with generalized dystonia responded to intravenous infusion of tiapride, a selective D‐2 dopamine antagonist, in an open trial (Arlazoroff et al. , 1991).…”

Section: D‐2 Dopamine Antagonistsmentioning

confidence: 99%

“…Dramatic improvement of motor functions during the treatment of psychosis by oral perphenazine (8-12 mg/ day) were observed in a case report presenting one patient with generalized dystonia (Harel and Giladi, 1990). Five patients with generalized dystonia responded to intravenous infusion of tiapride, a selective D-2 dopamine antagonist, in an open trial (Arlazoroff et al, 1991). Two open trials with clozapine (12.5-300 mg/ day) failed to establish any improvement in spasmodic torticollis (Thiel et al, 1994;Burbaud et al, 1998).…”

Section: D-2 Dopamine Antagonistsmentioning

confidence: 99%

See 1 more Smart Citation

Efficacy of pharmacological treatment of dystonia: evidence‐based review including meta‐analysis of the effect of botulinum toxin and other cure options

Balash

Giladi

2004

Euro J of Neurology

121

View full text Add to dashboard Cite

The treatment of both generalized and focal dystonia is symptomatic. There is no evidence-based information about the efficacy of the different methods of the pharmacological therapeutic options currently being applied in dystonia. The specific questions addressed by this study were which treatments for dystonia have proven efficacy and which of them have unproven results. Following evidence-based principles, a literature review based on MEDLINE and the Cochrane Library, augmented by manual search of the most important journals was performed to identify the relevant publications issued between 1973 and 2003. All articles appearing in the professional English literature, including case reports, were considered. In the presence of comparable studies the meta-analysis was performed to obtain pooled information and make a reasonable inference. Based on this review, we conclude: (i) botulinum toxin has obvious benefit (level A, class I-II evidence) for the treatment of cervical dystonia and blepharospasm; (ii) trihexyphenidyl in high dosages is effective for the treatment of segmental and generalized dystonia in young patients (level A, class I-II evidence); (iii) all other methods of pharmacological intervention for generalized or focal dystonia, including botulinum toxin injections, have not been confirmed as being effective according to accepted evidence-based criteria (level U, class IV studies).

show abstract

“…Five patients with generalized dystonia responded to intravenous infusion of tiapride, a selective D‐2 dopamine antagonist, in an open trial (Arlazoroff et al. , 1991).…”

Section: D‐2 Dopamine Antagonistsmentioning

confidence: 99%

Section: D-2 Dopamine Antagonistsmentioning

confidence: 99%

Efficacy of pharmacological treatment of dystonia: evidence‐based review including meta‐analysis of the effect of botulinum toxin and other cure options

Balash

Giladi

2004

Euro J of Neurology

121

View full text Add to dashboard Cite

show abstract

“…Dopamine antagonists, known to be partly effective in the treatment of dystonia (11,12), reduced the pain slightly. Dissection of the zygomaticotemporal branch of the CEPHALALGL4 18 (1998) facial nerve was followed by relief of blepharospasm.…”

Section: Discussionmentioning

confidence: 99%

Facial pain in a case of cranial dystonia: a case report

1998

View full text Add to dashboard Cite

A 76-year-old man had shown sustained excruciating facial pain in the maxillary region for more than 30 years. Since he was suffering from blepharospasm, facial electromyography was performed and revealed a perioral dystonia. This possible cause of facial pain might have been overlooked had dystonia not been considered and electromyographical studies performed. Repeated intramuscular perioral injections of botulinum toxin brought about complete pain relief. This case shows that involuntary activity of facial muscles can cause a severe chronic pain syndrome. Possible mechanisms include irritation of ascending trigeminal fibers, muscle ischemia due to compression of blood -vessels, or release of pain-producing substances.

show abstract

“…On top of these rather contrasting results from uncontrolled and small studies, the use of clozapine in practice may be limited by the necessity to regularly monitor hematologic parameters. Other atypical neuroleptics, such as olanzapine, risperidone and tiapride, have occasionally demonstrated marked to good improvement as well [Arlazoroff et al 1991; Zuddas and Cianchetti, 1996; Grassi et al 2000; Wohrle et al 2003; Lin and Chang, 2004].…”

Section: Oral Drug Therapymentioning

confidence: 99%

Current and future medical treatment in primary dystonia

Delnooz

Warrenburg

2012

Ther Adv Neurol Disord

View full text Add to dashboard Cite

Dystonia is a hyperkinetic movement disorder, characterized by involuntary and sustained contractions of opposing muscles causing twisting movements and abnormal postures. It is often a disabling disorder that has a significant impact on physical and psychosocial wellbeing. The medical therapeutic armamentarium used in practice is quite extensive, but for many of these interventions formal proof of efficacy is lacking. Exceptions are the use of botulinum toxin in patients with cervical dystonia, some forms of cranial dystonia (in particular, blepharospasm) and writer's cramp; deep brain stimulation of the pallidum in generalized and segmental dystonia; and high-dose trihexyphenidyl in young patients with segmental and generalized dystonia. In order to move this field forward, we not only need better trials that examine the effect of current treatment interventions, but also a further understanding of the pathophysiology of dystonia as a first step to design and test new therapies that are targeted at the underlying biologic and neurophysiologic mechanisms. http://tan.sagepub.com dystonia are given intramuscularly, often under electromyography (EMG) guidance, and need to be repeated every 3-6 months. Contraindications for the use of BoNT include history of neuromuscular disease, e.g. myasthenia gravis, LambertEaton syndrome or motor neuron disease, and a history of hypersensitivity to BoNT, albumin or saline. BoNT injections are also contraindicated in combination with aminoglycoside, penicillamine, quinine and calcium-channel blockers as the effect of these drugs may be potentiated. As teratogenicity of BoNT is still unknown, it is advised not to use BoNT during pregnancy and lactation. Keywords Cervical dystoniaBoNT injections are the first-line therapy for cervical dystonia (CD). Meta-analysis of several double-blind, placebo-controlled trials have demonstrated a beneficial effect of the BoNT type A (BoNT-A) versus placebo on multiple domains, such as dystonia severity, pain and the patient's and physician's subjective judgement. Adverse events are usually transient and mild. The most relevant side effects, of increasing frequency with higher doses and therefore dose-limiting, are neck weakness, dysphagia, dry mouth/sore throat and voice changes/hoarseness. Others are doseindependent and include pain at the site of injection, malaise, upper respiratory infection and headache [Costa et al. 2005b].BoNT also has proven long-term safety and efficacy. Several large case series have shown treatment efficacy up to 10 years, without longterm adverse effects [Blackie and Lees, 1990;Haussermann et al. 2004]. The occurrence of a secondary nonresponse, likely due to antibodies to BoNT or other components, was rare (1-2%) [Kessler et al. 1999;Haussermann et al. 2004;Brin et al. 2008]. Also primary nonresponse is seen, but reports documenting its occurrence are sparse [Truong et al. 2005]. A comparison of efficacy and safety between two preparations of BoNT-A, (onabotulinumtoxinA [Botox ® ] and rimabotulinumtoxin...

show abstract

Tiapride as Treatment for Certain Patients with Idiopathic Torsion Dystonia

Cited by 4 publications

References 0 publications

Efficacy of pharmacological treatment of dystonia: evidence‐based review including meta‐analysis of the effect of botulinum toxin and other cure options

Efficacy of pharmacological treatment of dystonia: evidence‐based review including meta‐analysis of the effect of botulinum toxin and other cure options

Facial pain in a case of cranial dystonia: a case report

Current and future medical treatment in primary dystonia

Contact Info

Product

Resources

About